0000950170-24-027509.txt : 20240306 0000950170-24-027509.hdr.sgml : 20240306 20240306201326 ACCESSION NUMBER: 0000950170-24-027509 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240304 FILED AS OF DATE: 20240306 DATE AS OF CHANGE: 20240306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yale Catriona CENTRAL INDEX KEY: 0001779308 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 24727836 MAIL ADDRESS: STREET 1: C/O AKERO THERAPEUTICS INC. STREET 2: 170 HARBOR WAY 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 ownership.xml 4 X0508 4 2024-03-04 0001744659 Akero Therapeutics, Inc. AKRO 0001779308 Yale Catriona C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 false true false false Chief Development Officer true Common Stock 2024-03-04 4 M false 10000 6.36 A 88415 D Common Stock 2024-03-04 4 M false 10646 21.09 A 99061 D Common Stock 2024-03-04 4 S false 20646 35.49 D 78415 D Stock Option (Right to Buy) 6.36 2024-03-04 4 M false 10000 0.00 D 2029-01-15 Common Stock 10000 15172 D Stock Option (Right to Buy) 21.09 2024-03-04 4 M false 10646 0.00 D 2029-12-12 Common Stock 10646 74354 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 23, 2023, previously adopted by the Reporting Person. Includes 505 shares acquired under the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan on June 30, 2023. The options are vested and currently exercisable. /s/ Jonathan Young, Attorney-in-Fact 2024-03-06